Basal insulin with glucagon-like peptide-1 receptor agonist could be preferred over premixed insulin for intensification in type 2 diabetes due to better glycemic control, lower hypoglycemia risk, and favorable effects on body weight. This evidence concerns the gene INS and type 2 diabetes mellitus.